1.Almuneef, MA. Molecular typing demonstrating transmission of gram-negative rods in a neonatal intensive care unit in the absence of a recognized epidemic. Clin Infect Dis 2001;32:220–227.
2.Singh, N, Patel, KM, Léger, MM, et al.Risk of resistant infections with Enterobacteriaceae in hospitalized neonates. Pediatr Infect Dis J 2002;21:1029–1033.
3.Toltzis, P. Molecular epidemiology of antibiotic-resistant gram-negative bacilli in a neonatal intensive care unit during a nonoutbreak period. Pediatrics 2001;108:1143–1148.
4.Bradford, PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933–951.
5.Hanberger, H, Erlandsson, M, Burman, LG, et al; ICU-STRAMA Study Group. High antibiotic susceptibility among bacterial pathogens in Swedish ICUs: report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand J Infect Dis 2004;36:24–30.
6.Jacoby, GA. Mechanisms of disease: the new β-lactamases. N Engl J Med 2005;352:380–391.
7.Couto, RC, Pedrosa, TM, Tofani Cde, P, Pedroso, ER. Risk factors for nosocomial infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2006;27:571–575.
8.Pfaller, MA, Segreti, J. Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamases. Clin Infect Dis 2006;42(suppl 4):S153–S163.
9.Rupp, ME, Fey, PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353–365.
10.Kanafani, ZA, Mehio-Sibai, A, Araj, GF, Kanaan, M, Kanj, SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control 2005;33:326–332.
11.Wu, TL, Chia, JH, Su, LH, Kuo, AJ, Chu, C, Chiu, CH. Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in pediatric intensive care units. J Clin Microbiol 2003;41:4836–4838.
12.Harris, AD, McGregor, JC, Furuno, JP. What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria? Clin Infect Dis 2006;43(suppl 2):S57–S61.
13.Briggs, S, Ussher, J, Taylor, S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae at Middlemore Hospital. N Z Med J 2005;118:U1563.
14.Cosgrove, SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(suppl 2):S82–S89.
15.Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI document. Wayne, PA: CLSI, 2007: M100-S17.
16.Jarlier, V, Nicolas, MH, Fournier, G, Philippon, A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867–878.
17.Healy, M. Microbial DNA typing by automated repetitive-sequence-based PCR. J Clin Microbiol 2005;43:199–207.
18.Saeed, S, Fakih, MG, Riederer, K, Shah, AR, Khatib, R. Interinstitutional and intrainstitutional transmission of a strain of Acinetobacter baumannii detected by molecular analysis: comparison of pulsed-field gel electrophoresis and repetitive sequence-based polymerase chain reaction. Infect Control Hasp Epidemiol 2006;27:981–983.
19.Bou, G, Cerveró, G, Dominguez, MA, Quereda, C, Martinez-Beltran, J. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii. Clin Microbiol Infect 2000;6:635–643.
20.Apisarnthanarak, A, Mundy, LM. Prevalence, treatment, and outcome of infection due to extended-spectrum β-lactamase–producing microorganisms. Infect Control Hosp Epidemiol 2006;27:326–327.
21.Calil, R. Reduction in colonization and nosocomial infection by multi-resistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. Am J Infect Control 2001;29:133–138.
22.Donskey, CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis 2006;43(suppl 2):S62–S69.
23.Thomson, KS, Moland, ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase–producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548–3554.
24.Saladin, M, Cao, VT, Lambert, T, et al.Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett 2002;209:161–168.
25.Sandiumenge, A, Diaz, E, Rodriguez, A, et al.Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006;57:1197–1204.
26.Takesue, Y, Ohge, H, Sakashita, M, et al.Effect of antibiotic heterogeneity on the development of infections with antibiotic-resistant gram-negative organisms in a non-intensive care unit surgical ward. World J Surg 2006;30:1269–1276.
27.Ibrahim, EH, Ward, S, Sherman, G, Kollef, MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000;117:1434–1442.
28.Benson, L, Sprague, B, Campos, J, Singh, N. Epidemiology of infection and colonization with vancomycin-resistant enterococci and frequency of cocolonization with methicillin-resistant Staphylococcus aureus in children. Infect Control Hosp Epidemiol 2007;28:880–882.
29.Sherer, CR, Sprague, BM, Campos, JM, et al.Characterizing vancomycin-resistant enterococci in neonatal intensive care. Emerg Infect Dis 2005;11:1470–1472.